KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis

  • STATUS
    Recruiting
  • End date
    May 26, 2022
  • participants needed
    60
  • sponsor
    Kadmon Corporation, LLC
Updated on 26 October 2021
platelet count
methotrexate
absolute neutrophil count
rheumatism
progressive systemic sclerosis
mycophenolate
raynaud's phenomenon
raynaud's syndrome
diffuse cutaneous systemic sclerosis
MRSS

Summary

This randomized, placebo-controlled phase 2 study is seeking to evaluate the efficacy and safety of belumosudil (KD025) for the treatment of diffuse cutaneous systematic sclerosis. Upon eligibility confirmation, a total of 60 adult subjects will be enrolled and randomized into 3 groups (1:1:1) to either receive orally administered belumosudil (200 mg once daily and 200 mg twice daily) or matched placebo for 28 weeks. Study drug dosing will be for 52 weeks: double-blinded for the first 28 weeks followed by an open-label extension of 24 weeks. After unblinding, the subjects on belumosudil will continue on the same belumosudil dose whereas the subjects in the placebo group will be re-randomized to one of the belumosudil doses.

Description

Systemic sclerosis (SSc) is a chronic autoimmune disease that causes widespread microvascular damage and excessive deposition of collagen in the skin and internal organs. Limited cutaneous systemic sclerosis is primarily cutaneous, affecting the hands, arms, and face. Diffuse cutaneous systemic sclerosis (dcSSc) is a more serious manifestation of the disease and is often rapidly progressive, not only involving the skin, but also involving internal organs including kidney, heart, and lungs.

Subjects who have signed an Institutional Review Board/Independent Ethics Committee-approved informed consent form and met all of the inclusion/exclusion criteria will be enrolled. A total of 60 subjects will be randomized into 3 groups (1:1:1) to receive orally administered belumosudil 200 mg once daily (QD; n = 20 subjects), belumosudil 200 mg twice daily (BID; n = 20 subjects), or matched placebo (n = 20 subjects) for 28 weeks. The study will be double-blinded for the first 28 weeks followed by an open-label extension of 24 weeks. After unblinding, the subjects in Group 1 and 2 will continue on the same belumosudil dose whereas the subjects in the placebo group will be re-randomized to either belumosudil 200 mg QD or belumosudil 200 mg BID in 1:1 fashion.

Details
Condition Scleroderma, Systemic sclerosis, Diffuse Scleroderma, diffuse cutaneous systemic sclerosis
Treatment Placebo, KD025, Belumosudil (KD025)
Clinical Study IdentifierNCT03919799
SponsorKadmon Corporation, LLC
Last Modified on26 October 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Male and female subjects 18 years old with the diagnosis of dcSSc according to the 2013 American College of Rheumatology and European League Against Rheumatism criteria
Must have disease duration (defined as interval from first non-Raynaud disease manifestation) of 5 years
Must have mRSS of 15 but 35
Active disease defined as any of the following within the 6 months prior to screening
Increase in mRSS by 3 units
Increase in mRSS by 2 units with involvement of 1 new body area
Involvement of 2 new body areas
Symptoms indicative of skin activity such as severe cutaneous itching or burning
Subjects receiving concomitant immunosuppression must be on a stable dose for at least 3 months prior to screening
Adequate organ and bone marrow functions evaluated during the 28 days prior to enrollment as follows
Absolute neutrophil count 1.5 10^9/L
Platelet count 100 10^9/L
Total bilirubin 1.0 upper limit of normal (ULN)
Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and serum creatinine 1.5 ULN
Female subjects of childbearing potential have a negative pregnancy test at screening. Females of childbearing potential are defined as sexually mature women without prior hysterectomy or who have had any evidence of menses in the past 12 months. However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, anti-estrogens, or ovarian suppression
Women of childbearing potential (i.e., menstruating women) must have a negative urine pregnancy test (positive urine tests are to be confirmed by serum test) documented within the 24-hour period prior to the first dose of study drug
Sexually active women of childbearing potential enrolled in the study must agree to use 2 forms of accepted methods of contraception during the course of the study and for 3 months after their last dose of study drug. Effective birth control includes (1) intrauterine device plus 1 barrier method; (2) on stable doses of hormonal contraception for at least 3 months (e.g., oral, injectable, implant, transdermal) plus 1 barrier method; or (3) two barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm), or a vasectomized partner
For male patients who are sexually active and who are partners of premenopausal women, agreement to use 2 forms of contraception as in Criterion Number 7 above during the treatment period and for at least 3 months after the last dose of study drug
Male subjects must not donate sperm for 3 months after last dose of study drug
Able to provide written informed consent prior to the performance of any study-specific procedures

Exclusion Criteria

Subject has corrected QT interval QTcF > 450 ms
Ongoing use or current use of concomitant medication known to have the potential for QTc prolongation
Female subject who is pregnant or breastfeeding
Participated in another study with an investigational drug within 28 days of study entry (for studies involving biologics within 3 half-lives of the biologic)
History or other evidence of severe illness or any other conditions that would make the subject, in the opinion of the Investigator, unsuitable for the study
Chronic heart failure with New York Heart Association Class II, III, or IV
Acute or chronic liver disease (e.g., cirrhosis)
Positive human immunodeficiency virus (HIV) test
Active hepatitis C virus (HCV), hepatitis B virus (HBV), or positive whole blood tuberculin test
Diagnosed with any malignancy within 3 years of enrollment, with the exception of basal cell or completely resected squamous cell carcinoma of the skin, resected in situ cervical malignancy, resected breast ductal carcinoma in situ, or low-risk prostate cancer after curative resection
Has had previous exposure to belumosudil or known allergy/sensitivity to belumosudil, or any other ROCK2 inhibitor
Scleroderma renal crisis within 4 months prior to enrollment
FVC 50% Predicted
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note